Live·Open questions in longevity research
All news
Science Research

Cryonics company Tomorrow Bio uses savings on its preservation solution to fund faster response times: it estimates a cost of 2000 euros per patient, while the ice blockers alone in Alcor’s M22 cost tens of thousands of euros

16 November 2026· 261116012

Cryonics company Tomorrow Bio uses savings on its preservation solution to fund faster response times: it estimates a cost of 2000 euros per patient, while the ice blockers alone in Alcor’s M22 cost tens of thousands of euros

The company uses its own VM1, a mixture of dimethyl sulfoxide (DMSO) and ethylene glycol, instead of M22, the solution used by the US organization Alcor. It explained its reasons in a video released on November 14.

To prevent ice from forming during cooling, blood is flushed out of the body and a cryoprotectant solution is pumped through the blood vessels. This process is called perfusion. A more concentrated solution provides more reliable protection against ice but is also more toxic to cells. The ice blockers in M22 are polymers that inhibit crystal formation, allowing a lower cryoprotectant concentration. According to the company, the ice blockers alone cost tens of thousands of euros per patient, while the entire VM1 solution costs about 2000.

The company acknowledges that M22 has been studied more extensively, including some use in kidney-freezing research, and that cell survival is slightly better with M22 in laboratory tests. However, patients cannot yet be revived, and their cell survival cannot be measured. The company therefore places greater importance on keeping tissue free of ice. When choosing its solution, it did not know which would preserve the brain better. It puts the savings toward faster deployment and a larger team:

“The benefits of better logistics, faster response times, less time without blood flow, and so on outweigh the potentially small advantages of M22 under laboratory conditions, particularly in kidneys.”

The cost of ice blockers has been questioned before. In a 2006 report, Cryonics Institute (CI) cryobiologist Yuri Pichugin concluded that reducing the required concentration of CI-VM-1, which also contains DMSO and ethylene glycol, from 55 to 52 % did not justify the increase in viscosity and cost. Concerns about the cheaper solution also have a history. A 2008 review on Biostasis.com states that more toxic solutions such as CI-VM-1 can immediately damage the endothelium, the lining of blood vessels. It also quotes Brian Wowk, one of M22’s developers: effective cryoprotection depends on effective perfusion, which in turn depends on intact blood vessels.

Perfusion is assessed using CT scans, which show what proportion of the brain received enough cryoprotectant to prevent ice formation. According to the company, this is 98–99 % of the brain in most of its cases, compared with 50–70 % at other organizations that publish CT scans. In Alcor’s report on case No. 259, the cerebral cortex reached 50–70 % of the final M22 concentration. No team had been on standby beforehand, perfusion began 8 hours after cardiac arrest, and it stopped, apparently because the patient’s blood vessels were obstructed. In Tomorrow Bio’s report on patient No. 26, the team had been on standby for a day. Perfusion began after 7 hours, more than two of which were spent obtaining a legal declaration of death. CT scans showed uniform distribution of the solution throughout the brain.

The company’s next goal is to obtain electron microscopy images of the brain, which reveal cell structure and the connections between cells. It is also choosing its solution with this assessment in mind. A second refinement involves substances that partially open the blood-brain barrier. The company explains that when the brain has been without blood flow for only a short time, this barrier remains intact: the solution draws water out but cannot enter, causing the brain to shrink. These substances are intended to open the barrier enough for water to leave and the solution to enter.

The team usually remains on standby near a critically ill patient and carries the solution in its vehicle. If death is expected within hours, it flies with its equipment but without the solution, because almost all airlines prohibit large volumes of liquid on board. Supplies of the solution are therefore stored in advance at locations across Europe and the US and driven to the patient. Clients are asked to store a kit in their garage or basement in exchange for a reduced fee.

Originally published on Telegram by Ukhvat NewsView on Telegram
Sources
#cryonics#cryoprotection#brain-perfusion#vm1#m22#vitrification